Showing results (71-80 of 161) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|February 7, 2001
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistanceB L Lum, S Kaubisch, G A Fisher, et al.
Transplantation Proceedings|December 31, 2022
Reduction in Maintenance Immunosuppression in Kidney Transplant Recipients With Stable Donor-Derived Cell-Free DNA Measurements: A Case SeriesErik L Lum, Arta Towns, Debargha Basuli, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2014
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib studyNa Xu, Charles H Redfern, Michael Gordon, et al.
Therapeutic Drug Monitoring|June 1, 1997
Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipientsJ E Charlebois, B L Lum, G F Cooney, et al.
Anti-Cancer Drugs|February 3, 2015
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidineHeidemarie Kletzl, Mylene Giraudon, Patricia Sanwald Ducray, et al.
Scientific Reports|January 20, 2018
A synthetic combinatorial approach to disabling deviant Hedgehog signalingC-W Fan, N Yarravarapu, H Shi, et al.
International Journal of Oral and Maxillofacial Surgery|November 1, 2019
Unusual metastatic presentations of a primary right parapharyngeal acinic cell adenocarcinomaC W Yong, J L Lum, A Makmur, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology GroupM W DeGregorio, B L Lum, W M Holleran, et al.
The Journal of Urology|January 1, 1992
Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomyJ H Reese, F S Freiha, A B Gelb, et al.
Psychopharmacology Bulletin|May 2, 1998
Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic settingP R Finley, B R Sommer, J L Corbitt, et al.
Pageof 17